News
$RNXT - RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Oct 7, 2026 · ThinkSabio Blog
$RNXT - RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
07-OCT-2026 08:31 AM ET
Share this post
💬 Comments
Loading comments…
Leave a comment
